A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
ACTIVE_NOT_RECRUITING
Status
Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Transformed Non-Hodgkin Lymphoma
- Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Marginal Zone Lymphoma
- Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Refractory Transformed Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Recurrent Central Nervous System Lymphoma
- Refractory Central Nervous System Lymphoma
Interventions
- BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy
- DRUG: Cyclophosphamide
- OTHER: Laboratory Biomarker Analysis
- PROCEDURE: Leukapheresis
- DRUG: Fludarabine Phosphate
Sponsor
Fred Hutchinson Cancer Center
Collaborators